Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
International Journal of Cancer|February 8, 2006
ErbB4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti-cancer therapyAlex Starr, Joel Greif, Akiva Vexler, et al.
The American Journal of Tropical Medicine and Hygiene|November 4, 2011
Spotted fever group rickettsiae in ticks collected from wild animals in IsraelAvi Keysary, Marina E Eremeeva, Moshe Leitner, et al.
Journal of Experimental Botany|June 15, 2021
Transcriptional up-regulation of host-specific terpene metabolism in aphid-induced galls of Pistacia palaestinaRachel Davidovich-Rikanati, Einat Bar, Gal Hivert, et al.
Journal of the National Cancer Institute|April 5, 2017
Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO TrialIsabelle Gingras, Eileen Holmes, Evandro De Azambuja, et al.
The Lancet. Oncology|August 10, 2016
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trialChristoph Zielinski, István Láng, Moshe Inbar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2005
Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trialChristoph Zielinski, Semir Beslija, Zrinka Mrsic-Krmpotic, et al.
Targeted Oncology|January 22, 2018
Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical ExperienceOfer Purim, Alexander Beny, Moshe Inbar, et al.
Scientific Data|April 13, 2022
Developing a large-scale dataset of flood fatalities for territories in the Euro-Mediterranean region, FFEM-DBKaterina Papagiannaki, Olga Petrucci, Michalis Diakakis, et al.
The New England Journal of Medicine|October 21, 2005
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancerMartine J Piccart-Gebhart, Marion Procter, Brian Leyland-Jones, et al.
Lancet (London, England)|December 11, 2012
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialChristina Davies, Hongchao Pan, Jon Godwin, et al.
Pageof 9